Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 12, Issue 4, 2011, Pages 483-490

  Pouleur, Anne Catherine ^a   Uno, Hajime ^a   Prescott, Margaret F ^b   Desai, Akshay ^a   Appelbaum, Evan ^c   Lukashevich, Valentina ^b   Smith, Beverly A ^b   Dahlöf, Björn ^d   Solomon, Scott D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Aldosterone; hypertension; left ventricular hypertrophy

Indexed keywords

ALDOSTERONE; ALISKIREN; LOSARTAN;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE MASS INDEX; HEART LEFT VENTRICLE WALL; HORMONE INHIBITION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBESITY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ALDOSTERONE; AMIDES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DEMOGRAPHY; FEMALE; FUMARATES; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; ORGAN SIZE; SYSTOLE;

EID: 83455201665     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320311414453     Document Type: Article

References (36)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990 ; 322: 1561-1566 (Pubitemid 20176696)
2. Matsumura K, Fujii K, Oniki H, Oka M, Iida M. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens. 2006 ; 19: 13-18 (Pubitemid 43217027)
3. Rocha R, Stier CT. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab. 2001 ; 12: 314
4. Weber KT, Brilla CG. Pathological hypertrophy andcardiac interstitium. Fibrosis and the renin-angiotensin-aldosterone system. Circulation. 1991 ; 83: 1849-1865
5. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C. Anigotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone salt-induced fibrosis. Hypertension. 1999 ; 33: 981-986 (Pubitemid 29186395)
6. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 1990 ; 67: 1355-1364
7. Young M. Adrenal steroids and cardiac fibrosis. Steroids. 1995 ; 60: 133-136
8. Robert V, Van Thiem N, Cheav SL, Mouas C, Swynghedauw B, Delcayre C. Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension. 1994 ; 24: 30-36 (Pubitemid 24195401)
9. Duprez DA, Bauwens FR, De Buyzere ML, De Backer TL, Kaufman JM, Van Hoecke J, et al. Influence of arterial pressure and aldosterone in left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol. 1993 ; 71: 17A - 20A (Pubitemid 23046407)
10. Denolle T, Chatellier G, Julien J, Battaglia C, Luo P, Plouin PF. Left ventricular mass and geometry before and after etiologic treatment in reno-vascular hypertension, aldosterone-producing adenoma, and pheochromocytoma. Am J Hypertens. 1993 ; 6: 907-913 (Pubitemid 23363177)
11. Jamieson A, Murdoch D, Kennedy JA, Connell JM. Left ventricular mass in hereditary human hypertension: glucocorticoid-suppressible hyperaldosteronism. J Hypertens. 1995 ; 13: 551-556
12. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000 ; 35: 580-586 (Pubitemid 30108152)
13. Muscholl MW, Schunkert H, Muders F, Elsner D, Kuch B, Hense HW, Riegger GA. Neurohormonal activity and left ventricular geometry in patients with essential hypertension. Am Heart J. 1998 ; 135: 58-66 (Pubitemid 28073059)
14. Velagaleti RS, Gona P, Levy D, Aragam J, Larson MG, Tofler GH, et al. Relations of biomarkers representing distinct biological pathways to left ventricular geometry. Circulation. 2008 ; 118: 2252-2258
15. Schunkert H, Hense HW, Muscholl M, Luchner A, Kürzinger S, Danser AH, Riegger GA. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart. 1997 ; 77: 24-31 (Pubitemid 27076910)
16. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina AC. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation. 1997 ; 95: 1471-1478 (Pubitemid 27142805)
17. Ghali JK, Liao Y, Cooper RS. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol. 1998 ; 31: 1635-1640 (Pubitemid 28273309)
18. Sullivan JM, Vander Zwaag RV, el-Zeky F, Ramanathan KB, Mirvis DM. LV hypertrophy: effect on survival. J Am Coll Cardiol. 1993 ; 22: 508-513
19. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991 ; 114: 345-352
20. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004 ; 292: 2343-2349 (Pubitemid 39491918)
21. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetrious V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004 ; 292: 2350-2356 (Pubitemid 39491919)
22. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation. 1997 ; 95: 2007-2014 (Pubitemid 27184266)
23. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003 ; 115: 41-46 (Pubitemid 36831120)
24. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK-21: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982 ; 4: 966-972 (Pubitemid 13204034)
25. Cleland JG, Dargie HJ, Hodsman GP, Ball SG, Robertson JI, Morton JJ, et al. Captopril in heart failure. A double blind controlled trial. Br Heart J. 1984 ; 52: 530-535 (Pubitemid 15208175)
26. Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther. 1995 ; 9: 145-149
27. Zannad F. Aldosterone and heart failure. Eur Heart J. 1995 ; 16: 98-102 (Pubitemid 26082328)
28. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, et al. Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009 ; 119: 530-537
29. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res. 2001 ; 29: 13-21 (Pubitemid 32236891)
30. Post WS, Larson MG, Levy D. Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study. Circulation. 1994 ; 90: 179-185 (Pubitemid 24203678)
31. Iso H, Kiyama M, Doi M, Nakanishi N, Kitamura A, Naito Y, et al Circulation. 1994: 1717-1724.
32. Ferrara LA, de Simone G, Pisanti N, Capone D, Fasano ML, Mancini M. Adrenergic nervous system and left ventricular mass in primary hypertension. Eur Heart J. 1989 ; 10: 1036-1040 (Pubitemid 20012835)
33. Devereux RB, Savage DD, Drayer JI, Laragh JH. Left ventricular hypertrophy and function in high, normal, and low-renin forms of essential hypertension. Hypertension. 1982 ; 4: 524-531 (Pubitemid 12017363)
34. Muscholl MW, Schunkert H, Muders F, Elsner D, Kuch B, Hense HW, et al. Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension. Am Heart J. 1998 ; 135: 58-66 (Pubitemid 28073059)
35. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003 ; 108: 1831-1838 (Pubitemid 37296092)
36. Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004 ; 110: 1456-1462 (Pubitemid 39238023)